An update on potential biomarkers for diagnosing diabetic foot ulcer at early stage - 19/12/20
pages | 11 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Potential Biomarkers for Diagnosing Diabetic Foot Ulcer at Early Stage.
Recently, in addition to traditional biomarkers of inflammation, along with the rapid development of systems biology, more and more biomarkers have emerged in the studies of genomics, proteomics, metabolomics, and microbiomics on diabetic foot ulcer. These biomarkers are beneficial to accurate diagnosis and risk stratification.
Highlights |
• | Diabetic foot ulcer seriously endangers the life quality of patients. |
• | Biomarkers play a key role in the accurate diagnosis and risk stratification of diabetic foot ulcer. |
• | There are many biomarkers emerging from the researches of systems biology such as genomics, proteomics, metabolomics, and microbiomics. |
Abstract |
As one of major chronic complications of diabetes, diabetic foot ulcer (DFU) is the main cause of disability and death. The clinical diagnosis and prognosis of DFU is inadequate. For clinicians, if the risk stratification of DFU can be obtained earlier in diabetic patients, the hospitalization, disability and mortality rate will be reduced.
In addition to the inflammatory biomarkers that have been widely concerned and used, e.g., procalcitonin, pentraxin-3, C-reactive protein (CRP), interleukins (ILs), and tumor necrosis factor-α (TNF-α), etc., a more comprehensive prediction of the risk and severity of DFU is needed to reflect new biomarkers for therapeutic intervention effects. Along with the development of systems biology technology, genomics, proteomics, metabolomics and microbiome have been used in the studies on DFU for better understanding of the disease. In this review, new biomarkers that are expected to assist in the accurate diagnosis and risk stratification of DFU will be discussed and summarized in detail.
Le texte complet de cet article est disponible en PDF.Abbreviations : AUCROC, BAFF, BCAAs, circRNA, CRP, DM, DF, DFI, DFU, DKD, eNOS, EPCs, ESR, ECM, RH, HC, HSP, HBOT, HIF, IDFU, IFN, ILs, LC–MS/MS, LO, LOX, MDC, MMPs, miRNAs, MVD, NETs, NH, NIDFU, PTCH1, WDFU, PTX-3, PCT, PAD4, RUNX1, SerpinB3, SNP, ST2, TARC, TLR6, TNF-α, T1DM, T2DM, VEGF, WBC
Keywords : Diabetic foot ulcer (DFU), Diabetes mellitus, Biomarkers, Diabetic complications, Inflammatory biomarkers, Systems biology
Plan
Vol 133
Article 110991- janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?